leisure time -WSS

leisure time

author：focus 2025-09-06 02:03:49 - browse：67

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Report captures long Covid’s disabling effects and policy challenges

WSS

Florida Supreme Court upholds state's abortion ban

Pancreatic cancer is often deadly, but new discoveries are raising hope

Stephen Quake on the Chan Zuckerberg quest to conquer disease

California wildfire smoke linked to 52,000 early deaths, study says

Coercive sterilizations revealed by STAT prompt outrage

First Opinion on colorectal cancer screening: letter and response

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Peter Hotez and the public health issue of online harassment

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

DIEP, the 'gold standard' of breast reconstruction, is under threat

Overprescribed: High cost isn't America's only drug problem

At least 13 dead in Texas as scorching temps continue

Oral obesity drug from Viking Therapeutics hits key early target

Sports medicine is finally prioritizing gender equality

Health care court cases: Humana, Sutter, Novant

Anesthesiologist group: stop taking Ozempic before surgery

Lilly's Alzheimer's drug donanemab backed by FDA advisers

explore

Republican states more likely to report Covid vaccine side effects

Scientific mystery highlights the blind spots in genomics databases

Young boy dies in trial for Pfizer Duchenne gene therapy

Cigna wins case to block Amy Bricker's move to CVS

Medical device trials still don't enroll enough women, study finds

UnitedHealth, in a surprise, takes aim at Steward’s physician group

explore

hotspot

Wikipedia

knowledge